Core Viewpoint - The first loss compensation insurance for shared scientific research instruments has been implemented in Suzhou, addressing long-standing issues related to equipment damage liability, thereby encouraging the sharing of high-end research instruments [2][3]. Group 1: Insurance Implementation - The insurance provides over 4 million yuan in risk coverage for large shared scientific research equipment at Suzhou University of Science and Technology [2]. - The insurance scheme integrates a "sharing economy + technology insurance" model, covering risks from design defects, installation errors, and operational mistakes [3]. Group 2: Impact on Research Institutions - The Suzhou University of Science and Technology has been providing technical support services for medical device and raw material R&D, owning high-end research instruments valued at over 10 million yuan [2]. - The insurance alleviates concerns about equipment damage, enabling the institution to fully utilize high-end equipment for comprehensive testing services [3]. Group 3: Future Directions - The municipal science and technology department plans to collaborate with instrument management departments, universities, and maintenance units to promote the use of more scientific instruments outside laboratories [3].

导读： 为持续激发民间投资活力，国家发展改革委进一步加大工作力度，近日组织集中向民间资本新推 介项目3200余个、涉及项目总投资超3万亿元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 2023年9月，国家发展改革委搭建了"全国向民间资本推介项目平台"，旨在推介各地梳理报 送的基础设施等领域优质项目，持续吸引民间资本。全国投资项目在线审批监管平台数据显 示，截止今年6月23日，全国正在向民间资本推介项目11751个、总投资额10.15万亿。 按照党中央、国务院决策部署，为持续激发民间投资活力，国家发展改革委进一步加大工作力 度，近日组织 集中向民间资本新推介 项目3200余个 、涉及项目总投资 超3万亿元 。 本批项目 聚焦交通运输、能源、水利、新型基础设施、城市基础设施、环保、仓储物流、制造 业等重点领域 ，依托"全国向民间资本推介项目平台"向社会公开推介。同时，组织各地建立 健全向民间资本推介项目专项工作协调机制，推动更多民间投资参与项目建设，加强跟踪协调 和对接服务，强化用地用海、环评等要素和融资支持，推动项目尽快落地实施。 下 ...

Core Viewpoint - The article highlights the market capitalization changes of major domestic life science instrument manufacturers in China for 2025, indicating a mixed performance with significant growth for some companies and declines for others due to policy impacts and market dynamics [1][2]. Market Capitalization Summary - The top five companies by market capitalization in 2025 are Mindray Medical, Sunny Optical, BGI Genomics, Antu Bio, and Haier Biomedical [2]. - A total of 10 companies experienced growth in market capitalization compared to 2024, with Zhongke Meiling leading at a growth rate of +130.44% [2]. - Four companies saw a decline in market capitalization, with Antu Bio experiencing the most significant drop at -26.70% [2]. Policy Impact Analysis - The medical anti-corruption and centralized procurement policies have negatively affected the revenue of several companies, leading to a 35% decrease in equipment bidding volume in tertiary hospitals [3]. - Mindray Medical, despite being an industry leader, faced a revenue growth drop from 25% to 9% due to procurement delays and budget constraints from DRG payment reforms [3]. - Antu Bio's revenue decreased by 18% in 2024 due to the impact of centralized procurement on the prices of chemical luminescence reagents [4]. Growth Drivers - Companies are shifting towards technology innovation as traditional high-margin models and bundled sales strategies become less viable under centralized procurement [5]. - Domestic microscope manufacturers have seen significant market capitalization growth, with Sunny Optical (+47.04%), Yongxin Optical (+27.11%), and Motic (+69.22%) benefiting from increased demand and technological advancements [7]. - Zhongke Meiling achieved a market share increase from 3% to 8% by overcoming technical barriers in ultra-low temperature freezing equipment [8]. International Expansion and Market Strategy - Companies are increasingly focusing on international markets to seek new growth opportunities, with Mindray Medical expanding its factory in New Jersey as part of its international strategy [8]. - BGI Genomics and Motic are also pursuing CE/FDA certifications to enter European and American markets, indicating a shift from domestic competition to global opportunities [8].

Core Viewpoint - The article emphasizes the importance of plasmid extraction in the life sciences industry, highlighting the need to understand the challenges faced by professionals in this area [1]. Group 1: Survey Details - A survey is being conducted to gather insights from life science professionals regarding their experiences with plasmid extraction [2]. - The survey is open from June 20 to July 6, with various prizes available for participants, including 50 Xiaomi backpacks, 50 stylish umbrellas, 10 Xiaomi Bluetooth speakers, and 3 Apple AirPods Max valued at 3,999 yuan each [2]. Group 2: Participation and Rewards - Participants can join the survey by scanning a QR code or clicking on a link provided at the end of the article, which takes approximately 30 seconds to complete [4]. - After the survey closes, the organizers will verify the responses and select winners for the prizes [5]. - The list of winners will be announced in an article published on July 18 on the "Instrument Information Network" public account [6].

Core Viewpoint - The FDA has announced an immediate review of clinical trials involving the transfer of live human cells from American citizens to laboratories in China and other "hostile countries" for genetic engineering, indicating a shift towards stricter biotechnology restrictions against China [4][5]. Group 1 - The FDA's review is prompted by concerns that international transfers and genetic engineering operations may occur without patient knowledge or consent, potentially leading to the misuse of sensitive genetic data by foreign governments, including those of hostile nations [5]. - The Biden administration's data security rules set in December 2024 included export controls but allowed a "comprehensive exemption" for clinical trial biological samples, creating regulatory loopholes that permitted participation from Chinese-funded enterprises [5]. - FDA Commissioner Marty Makary emphasized the importance of the integrity of the biomedical research system and stated that actions are being taken to protect patients, rebuild public trust, and defend America's biomedical leadership [5].

Core Viewpoint - Illumina announced the acquisition of SomaLogic for $350 million in cash, with potential performance-based milestones and royalties totaling up to $75 million, aimed at strengthening its position in the growing proteomics market and enhancing its multi-omics strategy [1][2]. Group 1: Acquisition Details - The acquisition includes SomaLogic's aptamer-based affinity proteomics platform, which will enhance Illumina's presence in the high-growth proteomics sector [2]. - Illumina expects the business to achieve profitability based on non-GAAP operating income by 2027, with non-GAAP operating margins aligning with Illumina by 2028 [2]. - The transaction is subject to customary closing conditions, including regulatory approvals, with completion anticipated in the first half of 2026 [2]. Group 2: Strategic Implications - Illumina's CEO emphasized that the acquisition will enhance the value of the NovaSeq X product and unlock greater capabilities in the future [1]. - The collaboration between Illumina and SomaLogic has been ongoing for over three years, improving service capabilities and accelerating the technological roadmap for advanced biomarker detection and disease analysis [1]. - The integration of SomaLogic's technology is expected to apply the scalability of NGS (Next-Generation Sequencing) to proteomics, maintaining an open and empowering NGS platform [1]. Group 3: Company Background - SomaLogic employs approximately 250 staff globally, with operations in Boulder, Colorado, including CLIA and CAP certified laboratories [2]. - Prior to the acquisition, Illumina and SomaLogic had a joint development agreement established in December 2021 to implement SomaScan proteomics detection on Illumina's NGS platform [3].

Core Viewpoint - The article emphasizes the importance of plasmid extraction in the life sciences industry, highlighting the need to understand the challenges faced by professionals in this area [1]. Group 1: Survey Details - A survey is being conducted to gather insights from life science professionals regarding their experiences with plasmid extraction [2]. - The survey is open from June 20 to July 6, with various prizes available for participants, including 50 Xiaomi backpacks, 50 stylish umbrellas, 10 Xiaomi Bluetooth speakers, and 3 Apple AirPods Max valued at 3,999 yuan each [2]. Group 2: Participation and Rewards - Participants can join the survey by scanning a QR code or clicking on a link provided at the end of the article, which takes approximately 30 seconds to complete [4]. - After the survey closes, the organizers will verify the responses and select winners for the prizes [5]. - The list of winners will be announced in an article published on July 18 on the "Instrument Information Network" public account [6].

Core Viewpoint - The article highlights the upcoming "11th International Conference on Electron Microscopy (iCEM 2025)" scheduled for June 24-27, 2025, focusing on advancements in electron microscopy technology and its applications, particularly in the semiconductor industry [1][2]. Group 1: Conference Overview - The iCEM 2025 aims to provide a free learning platform for researchers in electron microscopy, leveraging internet technology to overcome geographical barriers [1]. - The conference will feature six thematic sessions, including innovative applications of electron microscopy in semiconductor manufacturing and discussions on domestic electron microscope technology [2]. Group 2: Industry Demand and Trends - There has been a rapid increase in demand for electron microscopy technology in China's industrial sector, particularly in the semiconductor industry, where it is essential for defect analysis, process optimization, and device development [2]. - The conference will introduce a special session on "Innovative Applications of Electron Microscopy in Semiconductor Manufacturing," emphasizing the integration of industry, academia, and research [2]. Group 3: Conference Schedule - The conference will span four days, with various sessions dedicated to different aspects of electron microscopy, including in-situ/environmental electron microscopy, advanced electron microscopy, and applications in life sciences [3][4][5][6][7].

Core Viewpoint - Zhejiang University has announced procurement intentions for 41 items of laboratory equipment, with a total budget of 102 million yuan, scheduled for procurement between April and July 2025 [1][2]. Procurement Overview - The procurement includes various laboratory instruments such as enzyme labelers, multifunctional enzyme labelers, chemiluminescence imaging systems, portable ultrasound imaging systems, digital slide scanners, and microscopes [2][3]. - The total budget for the procurement is 102 million yuan, with specific allocations for different equipment types [2][3]. Equipment Details - Enzyme Labeler: 1 unit, budget 200,000 yuan, used for detecting absorbance in microplate samples [3]. - Multifunctional Enzyme Labeler: 1 unit, budget 200,000 yuan, supports multiple detection modes [3]. - Chemiluminescence Imaging System: 1 unit, budget 200,000 yuan, used for Western Blot and gel imaging [3]. - Portable Ultrasound Imaging System: 1 unit, budget 200,000 yuan, supports various examination modes [3]. - Microscopes: Multiple units including inverted microscopes, automatic tissue dehydrators, and fluorescence microscopes, with a total budget of 343,000 yuan [3][4]. - Digital Slide Scanner: 1 unit, budget 370,000 yuan, for high-resolution imaging [4]. - High-Throughput ICP-MS: 1 unit, budget 198,000 yuan, for ppt-level metal ion detection [4][5]. - Atomic Layer Deposition System: 1 unit, budget 160,000 yuan, for precise material deposition [4][5]. - Turbine Engine: 2 units, budget 770,000 yuan, for educational and research purposes [4][7]. Additional Equipment - Various other equipment such as long-focus spherical interferometers, sample preprocessing systems, and high-performance liquid chromatography-mass spectrometry systems are also included in the procurement list, with budgets ranging from 110,000 to 300,000 yuan [5][6][12][13][19]. - The procurement aims to enhance research capabilities and educational practices at Zhejiang University, particularly in fields like aviation, chemistry, and materials science [7][8].

Core Viewpoint - The revenue of multinational instrument companies in China has generally declined in 2024, with only Merck achieving growth, while many companies have experienced consecutive declines over the past two years due to multiple factors including US-China trade tensions, economic environment, and market competition [1][2]. Revenue Performance Summary - In 2024, Merck led the revenue rankings in China with $32.98 billion, marking a 5.8% increase after a 14.2% decline in 2023 [5][6]. - Danaher followed with $28.05 billion, down 10.8%, continuing a downward trend from $31.43 billion in 2023, which was a 13.0% decrease [6][8]. - Agilent ranked third with $12.20 billion, a decline of 11.6%, following a 7.9% drop in 2023 [7][8]. - Shimadzu and Mettler-Toledo ranked fourth and fifth with revenues of $6.30 billion and $6.22 billion, respectively, both experiencing declines [8]. - Overall, over 80% of the listed companies saw a year-on-year revenue decrease in 2024, with some companies facing declines for two consecutive years [8][14]. Market Share Analysis - The market share of many companies in China has also shown a downward trend, reflecting poor performance and indicating a relative decline in market vitality compared to global markets [9]. - In 2024, Agilent's market share in China was 18.74%, down from over 20% in previous years, indicating a significant drop [9]. Company-Specific Insights - Danaher reported that approximately 12% of its sales come from China, highlighting the potential adverse effects of the political, economic, and regulatory environment on its business [11]. - Waters experienced a notable 30% decline in sales in China, attributed to decreased demand across various customer categories due to economic conditions and trade tensions [12]. - Agilent's revenue decline was primarily driven by pressures in capital spending from clients, particularly in the pharmaceutical market [12]. - Mettler-Toledo emphasized the importance of the Chinese market, which accounted for 16% of its external sales, and noted the impact of geopolitical tensions and economic pressures on its performance [13]. Strategic Adjustments - In response to market changes, multinational companies are accelerating strategic adjustments, increasing investment in local R&D, and launching products tailored to local needs [15]. - Despite the challenges faced from 2022 to 2024, the long-term potential of the Chinese market remains significant, and companies are expected to adapt more flexibly and innovatively to maintain competitiveness [15].